34.22MMarket Cap-434P/E (TTM)
0.4072High0.3900Low514.84KVolume0.4000Open0.3980Pre Close205.69KTurnover0.90%Turnover RatioLossP/E (Static)85.68MShares1.818052wk High-1.40P/B22.88MFloat Cap0.339052wk Low--Dividend TTM57.28MShs Float8.7300Historical High--Div YieldTTM4.32%Amplitude0.3390Historical Low0.3990Avg Price1Lot Size
Unicycive Therapeutics Stock Forum
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
Unicycive Therapeutics (Nasdaq: UNCY) has been granted U.S. Patent No. 12,036,211 by the USPTO for UNI-494, ensuring intellectual property protection until 2040. The patent covers a method of treating acute kidney injury or contrast-induced nephropathy using the UNI-494 compound, a novel nicotinamide ester derivative and sele...
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company committed to developing therapies for patients with kidney disease, recently announced promising initial results from a patient-reported outcome survey conducted during their pivotal clinical ...
No comment yet